Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Mural Oncology plc Ordinary Shares

We know that drug development is both an art and a science.

The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us.

Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living.

Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. 

Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies.  

We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective.

Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)


Mural Oncology

Today marks a notable milestone as Mural Oncology officially launches as an independent, publicly traded, clinical-stage immuno-oncology company. Tomorrow, find us on Nasdaq as $MURA.

Mural's dedication to advancing our pipeline of novel engineered cytokine immunotherapies with our lead candidate, nemvaleukin alfa, is backed by a strong foundation of $275 million in committed funding, and a clear vision to reimagine cytokine-based immunotherapies for the treatment of cancer. 

Our mission is simple: to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Learn more:  https://bit.ly/47AUnhN #oncology #biotechnology #innovation #immunooncology #Nasdaq

	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
revenue
cost of revenue			530K -				846K -
gross profit			-530K -				-846K -
selling and marketing expenses			-130K -				-546K -
general and administrative expenses	4.53M -	12.31M 171.89%	3.75M 69.58%	6.70M 78.91%	5.96M 11.09%	16.27M 173.03%	7.17M 55.96%	6.73M 6.03%	6.51M 3.27%
selling general and administrative expenses	4.53M -	12.31M 171.89%	3.62M 70.64%	6.70M 85.34%	5.96M 11.09%	16.27M 173.03%	6.62M 59.32%	6.73M 1.72%	6.51M 3.27%
research and development expenses	44.77M -	45.27M 1.11%	40.01M 11.62%	42.70M 6.72%	40.35M 5.49%	42.24M 4.68%	26.57M 37.11%	27.54M 3.67%	27.59M 0.15%
other expenses							3.12M -
cost and expenses	49.30M -	57.59M 16.80%	44.16M 23.32%	49.40M 11.88%	46.31M 6.25%	58.51M 26.34%	34.03M 41.84%	34.28M 0.72%
operating expenses	49.30M -	57.59M 16.80%	43.63M 24.24%	49.40M 13.24%	46.31M 6.25%	58.51M 26.34%	33.19M 43.28%	34.28M 3.28%	34.10M 0.52%
interest expense
ebitda	-48.93M -	-57.09M 16.67%	-43.63M 23.58%	-48.76M 11.76%	-45.53M 6.61%	-57.90M 27.16%	-33.19M 42.68%	-31.56M 4.89%
operating income	-49.30M -	-57.59M 16.80%	-44.16M 23.32%	-49.40M 11.88%	-46.31M 6.25%	-58.51M 26.34%	-34.03M 41.84%	-31.56M 7.25%
depreciation and amortization	372K -	497K 33.60%	530K 6.64%	645K 21.70%	779K 20.78%	613K 21.31%	846K 38.01%
total other income expenses net						951K -	3.12M 227.66%
income before tax	-49.30M -	-57.59M 16.80%	-44.16M 23.32%	-49.40M 11.88%	-46.31M 6.25%	-57.56M 24.29%	-30.92M 46.29%	-31.56M 2.09%	-31.76M 0.62%
income tax expense	1.34M -	1.22M 9.02%	2.31M 89.43%	2.91M 25.79%	4.97M 70.83%	1.98M 60.23%	1 100.00%
net income	-50.64M -	-58.80M 16.11%	-46.47M 20.98%	-52.31M 12.57%	-51.28M 1.97%	-59.54M 16.10%	-30.92M 48.07%	-31.56M 2.09%	-31.76M 0.62%
weighted average shs out	16.69M -		16.69M -		16.69M -		16.79M -	16.92M 0.78%	17.03M 0.61%
weighted average shs out dil	16.69M -		16.69M -		16.69M -		16.79M -	16.92M 0.78%	17.03M 0.61%
eps	-3.03 -	0 100%	-2.78 Infinity%	0 100%	-3.07 Infinity%	0 100%	-1.84 Infinity%	-1.86 1.09%	-1.87 0.54%
epsdiluted	-3.03 -	0 100%	-2.78 Infinity%	0 100%	-3.07 Infinity%	0 100%	-1.84 Infinity%	-1.86 1.09%	-1.87 0.54%

MURA

COM:MURALONCOLOGY

Mural Oncology plc

Last Close

3.37

22/11 21:00

Market Cap

57.15M

Beta: -

Volume Today

35.85K

Avg: -

Preview